-Omic technologies represent a novel approach to unravel ill-defined aspects of psoriatic arthritis (PsA). Large-scale information can be acquired from analysis of affected tissues in PsA via high-throughput studies in the domains of genomics, transcriptomics, epigenetics, proteomics and metabolomics. This is a critical overview of the current knowledge of -omics in PsA, with emphasis on the pathophysiological insights of diagnostic and therapeutic relevance, the advent of novel biomarkers and their potential use for precision medicine in PsA. - [Display omitted] • Strong genetic component in psoriatic arthritis which is higher than in psoriasis. • Polymorphisms in the IL-23/IL-17 axis and the JAK/STAT signaling pathway • Epigenetic modifications may account for the missing heritability. • Transcriptomic/proteomic studies consistent with a TNF/IL-17 polarized cell response and JAK signaling. • Metabolomic fingerprints of high inflammatory and cardiometabolic burden. [ABSTRACT FROM AUTHOR]